Open Access

Disparities in long‑term outcomes between benign and malignant diseases after Hartmann's procedure: A retrospective observational study 

  • Authors:
    • Ken Imaizumi
    • Hiroyuki Kasajima
    • Aya Sato
    • Kentaro Sato
    • Keiichiro Ito
    • Takumu Fukasawa
    • Kentaro Ichimura
    • Tadashi Odagiri
    • Daisuke Yamana
    • Yosuke Tsuruga
    • Minoru Umehara
    • Michihiro Kurushima
    • Kazuaki Nakanishi
  • View Affiliations

  • Published online on: May 15, 2025     https://doi.org/10.3892/mco.2025.2859
  • Article Number: 64
  • Copyright: © Imaizumi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The long‑term course following Hartmann's procedure (HP) has not yet been clarified. The present study aimed to compare the achievement of stoma reversal between benign and malignant diseases, and explore post‑reversal long‑term outcomes. Patients who underwent HP between June 2005 and December 2021 at a single center were retrospectively evaluated. The primary endpoint was the difference in stoma‑reversal rate between benign and malignant diseases. The secondary endpoints were identification of the predictive factors for stoma reversal and comparison of stoma‑free survival and anorectal functions after reversal between patients with benign and malignant diseases. Among 261 patients, the benign and malignant disease groups comprised 102 and 159 patients, respectively. Malignant disease (P=0.044), low Charlson's comorbidity index (P<0.001), urgent HP (performed as a lifesaving procedure; P=0.003) and home discharge (P<0.001) were significantly associated with stoma reversal in the multivariate analysis. Furthermore, cumulative stoma‑reversal rate was significantly lower in the malignant disease than in the benign disease group (P<0.001). In 44 patients who underwent stoma reversal, the rate of stoma‑free survival in the malignant disease group was significantly reduced compared with that in the benign disease group at 10 years after reversal (P=0.004). No significant between‑group differences were observed regarding anorectal function (n=24). In conclusion, the achievement of stoma reversal and the stoma‑free survival rate after reversal may be lower in patients with malignant disease than in those with benign disease; however, anorectal function after reversal may not be markedly different. 
View Figures
View References

Related Articles

Journal Cover

July-2025
Volume 23 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Imaizumi K, Kasajima H, Sato A, Sato K, Ito K, Fukasawa T, Ichimura K, Odagiri T, Yamana D, Tsuruga Y, Tsuruga Y, et al: Disparities in long‑term outcomes between benign and malignant diseases after Hartmann's procedure: A retrospective observational study&nbsp;. Mol Clin Oncol 23: 64, 2025.
APA
Imaizumi, K., Kasajima, H., Sato, A., Sato, K., Ito, K., Fukasawa, T. ... Nakanishi, K. (2025). Disparities in long‑term outcomes between benign and malignant diseases after Hartmann's procedure: A retrospective observational study&nbsp;. Molecular and Clinical Oncology, 23, 64. https://doi.org/10.3892/mco.2025.2859
MLA
Imaizumi, K., Kasajima, H., Sato, A., Sato, K., Ito, K., Fukasawa, T., Ichimura, K., Odagiri, T., Yamana, D., Tsuruga, Y., Umehara, M., Kurushima, M., Nakanishi, K."Disparities in long‑term outcomes between benign and malignant diseases after Hartmann's procedure: A retrospective observational study&nbsp;". Molecular and Clinical Oncology 23.1 (2025): 64.
Chicago
Imaizumi, K., Kasajima, H., Sato, A., Sato, K., Ito, K., Fukasawa, T., Ichimura, K., Odagiri, T., Yamana, D., Tsuruga, Y., Umehara, M., Kurushima, M., Nakanishi, K."Disparities in long‑term outcomes between benign and malignant diseases after Hartmann's procedure: A retrospective observational study&nbsp;". Molecular and Clinical Oncology 23, no. 1 (2025): 64. https://doi.org/10.3892/mco.2025.2859